The PAHcare™ medical device being assessed in this clinical investigation has been approved in Europe as a Class I investigation medical device as per Medical Devices Directive (93/42/EEC) for its use by pulmonary arterial hypertension patients (26 March 2021, reference number 1291298). The authors say this is the first study that will examine the effects of using mHealth strategies in patients with pulmonary arterial hypertension.
In this prospective study, 50 PAH patients will be recruited from specialized units across six reference hospitals in the Spanish healthcare system. The PAHcare™ digital health platform enables patients to track their health and lifestyle, receive educational content, medication reminders, and remote coaching from healthcare providers. The evaluation will primarily assess the platform’s impact on patients’ health-related quality of life (HRQoL) through electronic questionnaires.
Full article is available at this link on the Frontiers website
Looking forward to findings!
Frontiers Public Health, 07 December 2022, Section Digital Public Health, Volume 10 – 2022 https://doi.org/10.3389/fpubh.2022.954487